Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini
- PMID: 8276724
- PMCID: PMC5919086
- DOI: 10.1111/j.1349-7006.1993.tb02821.x
Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini
Abstract
Amino acid-degrading enzymes are known to inhibit the growth of tumor cells in culture by depleting amino acids in the medium. Here we demonstrate that arginine deiminase (EC 3.5.3.6) from Mycoplasma arginini had stronger growth-inhibitory activity against all 4 kinds of tumor cell lines tested than L-asparaginase and arginase, which are well-known anti-tumor enzymes. Next, chemical modification of the arginine deiminase molecule with polyethylene glycol was shown to enhance its potency as an anti-tumor enzyme. The percentage of modified amino groups per molecule was estimated to be 51% of the total amino groups, and the average molecular weight was estimated to be about 400,000 by gel-filtration HPLC. The enzymic activity of the modified enzyme was 25.5 units/mg protein, which was equivalent to 57% of that of the native enzyme. The modified enzyme strongly inhibited growth of a mouse hepatoma cell line, MH134, at a concentration of more than 10 ng/ml, showing almost the same dose-response curve as the native enzyme. When a bolus of 5 units of the modified enzyme was intravenously injected into male BDF1 mice, L-arginine in the blood completely disappeared within 5 min, and remained undetectable for more than 8 days. On the other hand, in the case of bolus injection of the same number of units of native enzyme, the plasma L-arginine level recovered up to 66% of the control level at 8 days. These results suggest that this modified enzyme has a longer plasma clearance time and may be more effective as a new anti-tumor agent than the native enzyme.
Similar articles
-
Anti-tumor activity of arginine deiminase from Mycoplasma argini and its growth-inhibitory mechanism.Jpn J Cancer Res. 1995 Sep;86(9):840-6. doi: 10.1111/j.1349-7006.1995.tb03094.x. Jpn J Cancer Res. 1995. PMID: 7591961 Free PMC article.
-
In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini.Int J Cancer. 1992 May 8;51(2):244-9. doi: 10.1002/ijc.2910510213. Int J Cancer. 1992. PMID: 1568792
-
Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.Bioconjug Chem. 2006 Nov-Dec;17(6):1447-59. doi: 10.1021/bc060198y. Bioconjug Chem. 2006. PMID: 17105223
-
Arginine Deiminase Enzyme Evolving as a Potential Antitumor Agent.Mini Rev Med Chem. 2018;18(4):363-368. doi: 10.2174/1389557516666160817102701. Mini Rev Med Chem. 2018. PMID: 27538511 Review.
-
Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug.Appl Microbiol Biotechnol. 2016 Jun;100(11):4747-60. doi: 10.1007/s00253-016-7490-z. Epub 2016 Apr 18. Appl Microbiol Biotechnol. 2016. PMID: 27087524 Review.
Cited by
-
Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures.Br J Cancer. 2003 Feb 24;88(4):613-23. doi: 10.1038/sj.bjc.6600681. Br J Cancer. 2003. PMID: 12592378 Free PMC article.
-
The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma.Drug Target Insights. 2007;2:119-28. Epub 2007 Jun 15. Drug Target Insights. 2007. PMID: 21901069 Free PMC article.
-
A modified arginine-depleting enzyme NEI-01 inhibits growth of pancreatic cancer cells.PLoS One. 2020 Apr 30;15(4):e0231633. doi: 10.1371/journal.pone.0231633. eCollection 2020. PLoS One. 2020. PMID: 32353864 Free PMC article.
-
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.Br J Cancer. 2010 Sep 28;103(7):954-60. doi: 10.1038/sj.bjc.6605856. Epub 2010 Aug 31. Br J Cancer. 2010. PMID: 20808309 Free PMC article. Clinical Trial.
-
Anti-tumor activity of arginine deiminase from Mycoplasma argini and its growth-inhibitory mechanism.Jpn J Cancer Res. 1995 Sep;86(9):840-6. doi: 10.1111/j.1349-7006.1995.tb03094.x. Jpn J Cancer Res. 1995. PMID: 7591961 Free PMC article.
References
-
- ) Broom , J. D.Evidence that the L‐asparaginase activity of guinea pig serum is responsible for its antilymphoma effects . Nature , 191 , 1114 – 1115 ( 1961. ).
-
- ) Mashburn , L. T. and Wriston , J. C.Tumor inhibitory effect of L‐asparaginase from Escherichia coli . Arch. Biochem. Biophys. , 105 , 450 – 452 ( 1964. ). - PubMed
-
- ) Burton , A. F.The effect of arginase on tumor cells . Proc. Am. Assoc. Cancer Res. , 10 , 12 ( 1969. ).
-
- ) Weider , J. K. , Palczuk , N. C. , van Es , T. and Davis , F. F.Some properties of polyethylene glycol: phenylalanine ammonia‐lyase adducts . J. Biol. Chem. , 254 , 12579 – 12587 ( 1979. ). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials